Neoadjuvant Treatment of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Triple-Negative or Her2 Positive Breast Cancer (NATT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00912444

Recruitment Status : Terminated (TAC treatment was associated with better survial outcome compared with TC treatment, we terminated recruiting and waiting for longer follow up period.)

First Posted : June 3, 2009

Last Update Posted : November 22, 2016

Sponsor:

Information provided by (Responsible Party):

Kunwei Shen, Shanghai Jiao Tong University School of Medicine

Study Description

Brief Summary:

The purpose of this study is to compare the pathological complete response (pCR) rate in triple-negative or Her2 positive breast cancer patients treated with neoadjuvant docetaxel, anthracycline and cyclophosphamide (TAC) or docetaxel and cyclophosphamide (TC) regimen.

Condition or disease	Intervention/treatment	Phase
Breast Cancer	Drug: Docetaxel, Anthracycline (Doxorubicin or Epirubicin), Cyclophosphamide Drug: Docetaxel, cyclophosphamide	Phase 3

Detailed Description:

Breast cancer is the leading cause of cancer in women in China. Neoadjuvant chemotherapy for treatment of locally advanced breast cancer has become a standard therapy. Results from neoadjuvant trials have shown that pathological complete response (pCR) is an independent predictor of outcome. Docetaxel was introduced into clinical practice in the early 1990s and has demonstrated good activity in the adjuvant and metastatic settings. Both TC and TAC are effective regimens in the adjuvant setting. The most optimal regimen in the neoadjuvant treatment is however unknown. This is especially true in triple-negative or HER2 positive breast cancer. This study will evaluate the pCR rate of TAC and TC as neoadjuvant treatment for triple-negative or HER2 positive breast cancer.

Study Design


Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	102 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	None (Open Label)
Primary Purpose:	Treatment
Official Title:	A Multi-Center, Randomized Study of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Neoadjuvant Treatment of Triple-Negative or Her2 Positive Breast Cancer
Study Start Date :	July 2009
Actual Primary Completion Date :	May 2012
Actual Study Completion Date :	October 2015

Resource links provided by the National Library of Medicine

Genetics Home Reference related topics: Breast cancer

MedlinePlus related topics: Breast Cancer

Drug Information available for: Cyclophosphamide Docetaxel

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Experimental: TAC Arm six cycles of neoadjuvant Docetaxel, Anthracycline and Cyclophosphamide	Drug: Docetaxel, Anthracycline (Doxorubicin or Epirubicin), Cyclophosphamide Docetaxel 75mg/m2, doxorubicin 50mg/m2 or epirubicin 60mg/m2, cyclophosphamide 500mg/m2 every 3 weeks for six cycles
Experimental: TC Arm six cycles of neoadjuvant Docetaxel and Cyclophosphamide	Drug: Docetaxel, cyclophosphamide Docetaxel 75mg/m2, cyclophosphamide 600mg/m2 every 3 weeks for six cycles

Outcome Measures

Primary Outcome Measures :

pathological complete remission (pCR) rate [ Time Frame: after 6 cycles of neoadjuvant therapy ]

Secondary Outcome Measures :

disease free survival (DFS) and overall survival (OS) [ Time Frame: 5-year ]
clinical response rate [ Time Frame: after 6 cycles of neoadjuvant therapy ]
safety profile [ Time Frame: during neoadjuvant therapy ]
breast conservation therapy (BCT) rate [ Time Frame: after surgery ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	18 Years to 70 Years (Adult, Older Adult)
Sexes Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Women aged ≥ 18 years and < 70 years
Karnofsky performance status (KPS) ≥ 70
At least one measurable disease according to the RECIST. histologically confirmed invasive breast cancer (excluding inflammatory breast cancer), T2N1 or locally advanced breast cancer (T3-4N0-3 or T0-4N2-3)
Biopsy specimens are available for ER, PgR and Her2 detection, patients should be with triple negative or Her2 positive breast cancer, Her2 positivity is defined as FISH/CISH Her2 positive or IHC Her2 3+, Triple-negative disease defined as negativity for ER, PgR and Her2
Adequate bone marrow function: Neutrophil ≥ 1.5*109/L; Hb ≥ 100g/L; PLT ≥ 100*109/L
An estimated life expectancy of at least 12 months
Willing to take biopsy before neoadjuvant chemotherapy and patients must be accessible for treatment and follow-up
Women with potential child-bearing must have a negative pregnancy test (urine or serum) within 7 days of drug administration and agree to use an acceptable method of birth control to avoid pregnancy for the duration of the study
Written informed consent according to the GCP

Exclusion Criteria:

Prior systemic or loco-regional treatment of breast cancer, including chemotherapy
Metastatic breast cancer
With a history of malignant tumor except uterine cervix cancer in situ or skin basal cell carcinoma
Patients with medical conditions that indicate intolerant to neoadjuvant therapy and related treatment, including uncontrolled pulmonary disease, diabetes mellitis, severe infection, active peptic ulcer, coagulation disorder, connective tissue disease or myelo-suppressive disease
inadequate liver function (bilirubin > 1.0 times upper normal limit [UNL] and ALT and/or AST> 1.5 UNL associated with alkaline phosphatase > 2.5 UNL; inadequate renal function (creatinine > 1.0 times UNL and in case of limit value, Creatinine clearance < 60 ml/min)
Contraindication for using dexamethasone
History of congestive heart failure, uncontrolled or symptomatic angina pectoris, arrhythmia or myocardial infarction; poorly controlled hypertension (systolic BP > 180 mmHg or diastolic BP > 100 mmHg)
Has peripheral neuropathy ≥ grade 1
Patient is pregnant or breast feeding
Known severe hypersensitivity to any drugs in this study
Treatment with any investigational drugs within 30 days before the beginning of study treatment

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00912444

Locations


China, Guangdong
The First People's Hospital of Foshan
Foshan, Guangdong, China, 528000
Guangdong Provincial Maternal and Child Health Hospital
Guangzhou, Guangdong, China, 510010
Guangzhou General Hospital of Guangzhou Military Area
Guangzhou, Guangdong, China, 510010
China, Hunan
Xiangya Hospital Central South University
Changsha, Hunan, China, 410008
Hunan Cancer Hospital
Changsha, Hunan, China, 410009
China, Jiangsu
Jiangyin People's Hospital
Jiangyin, Jiangsu, China, 214440
Jiangsu Cancer Hospital
Nanjing, Jiangsu, China, 210009
The Second Affilliated Hospital of Suzhou University
Suzhou, Jiangsu, China, 215004
Wujiang First People's Hospital
Wujiang, Jiangsu, China, 215200
China, Jiangxi
The third hospital of Nanchang
Nanchang, Jiangxi, China, 330009
China, Shandong
Linyi People's Hospital
Linyi, Shandong, China, 276003
China, Shanghai
Shanghai Obstetrics and Gynecology Hospital
Shanghai, Shanghai, China, 200021
Ruijin Hospital
Shanghai, Shanghai, China, 200025
Zhongshan Hospital Fudan University
Shanghai, Shanghai, China, 200032
the International Peace Maternity and Child health Hospital
Shanghai, Shanghai, China, 200033
Xin Hua Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai, China, 200092
China, Shanxi
Shanxi Provincical Cancer Hospital
Taiyuan, Shanxi, China, 030013
Fisrt Affiliated Hospital of Medical College of Xi'an Jiaotong University
Xi'an, Shanxi, China, 710061
China, Sichuan
West China Hospital Sichuan University
Chengdu, Sichuan, China, 610041
China, Xinjiang
Sinkiang Uygur Autonomous Region Cancer Hospital
Urumqi, Xinjiang, China, 830000
China, Yunnan
Yunnan Provincical Tumor Hospital
Kunming, Yunnan, China, 650106
China, Zhejiang
Obstetrics and Gynecology Hospital affiliated to Zhejiang University
Hangzhou, Zhejiang, China, 310006
Zhejiang Traditional Chinese Medical Hospital
Hangzhou, Zhejiang, China, 310006
Ningbo First People's Hospital
Ningbo, Zhejiang, China, 315010
Taizhou Hospital of Zhejiang Province
Taizhou, Zhejiang, China, 318050
The First Affilliated Hospital of Wenzhou Medical College
Wenzhou, Zhejiang, China, 325000
Ruian People's Hospital
Wenzhou, Zhejiang, China, 325208

Sponsors and Collaborators

Shanghai Jiao Tong University School of Medicine

Investigators


Principal Investigator:	Kunwei Shen	Shanghai Jiao Tong University School of Medicine

More Information

Additional Information:

published result link This link exits the ClinicalTrials.gov site

Publications:

Yang L, Li LD, Chen YD, Parkin DM. [Time trends, estimates and projects for breast cancer incidence and mortality in China]. Zhonghua Zhong Liu Za Zhi. 2006 Jun;28(6):438-40. Chinese.

Jones SE, Savin MA, Holmes FA, O'Shaughnessy JA, Blum JL, Vukelja S, McIntyre KJ, Pippen JE, Bordelon JH, Kirby R, Sandbach J, Hyman WJ, Khandelwal P, Negron AG, Richards DA, Anthony SP, Mennel RG, Boehm KA, Meyer WG, Asmar L. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol. 2006 Dec 1;24(34):5381-7. Erratum in: J Clin Oncol. 2007 May 1;25(13):1819.

Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, Tomiak E, Al-Tweigeri T, Chap L, Juhos E, Guevin R, Howell A, Fornander T, Hainsworth J, Coleman R, Vinholes J, Modiano M, Pinter T, Tang SC, Colwell B, Prady C, Provencher L, Walde D, Rodriguez-Lescure A, Hugh J, Loret C, Rupin M, Blitz S, Jacobs P, Murawsky M, Riva A, Vogel C; Breast Cancer International Research Group 001 Investigators. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005 Jun 2;352(22):2302-13.

Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005 Aug 15;11(16):5678-85.


Responsible Party:	Kunwei Shen, Professor, Shanghai Jiao Tong University School of Medicine
ClinicalTrials.gov Identifier:	NCT00912444 History of Changes
Other Study ID Numbers:	NATT
First Posted:	June 3, 2009 Key Record Dates
Last Update Posted:	November 22, 2016
Last Verified:	November 2016

Keywords provided by Kunwei Shen, Shanghai Jiao Tong University School of Medicine:


Breast Neoplasms Neoadjuvant Chemotherapy	Docetaxel Cyclophosphamide Anthracycline

Additional relevant MeSH terms:


Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Cyclophosphamide Docetaxel Liposomal doxorubicin Doxorubicin Epirubicin Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs	Antirheumatic Agents Antineoplastic Agents, Alkylating Alkylating Agents Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Myeloablative Agonists Tubulin Modulators Antimitotic Agents Mitosis Modulators Antibiotics, Antineoplastic Topoisomerase II Inhibitors Topoisomerase Inhibitors Enzyme Inhibitors

To Top